Michael Evans‐Brown

1.4k total citations
28 papers, 700 citations indexed

About

Michael Evans‐Brown is a scholar working on Toxicology, Clinical Psychology and Epidemiology. According to data from OpenAlex, Michael Evans‐Brown has authored 28 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Toxicology, 4 papers in Clinical Psychology and 4 papers in Epidemiology. Recurrent topics in Michael Evans‐Brown's work include Forensic Toxicology and Drug Analysis (13 papers), Psychedelics and Drug Studies (4 papers) and Substance Abuse Treatment and Outcomes (3 papers). Michael Evans‐Brown is often cited by papers focused on Forensic Toxicology and Drug Analysis (13 papers), Psychedelics and Drug Studies (4 papers) and Substance Abuse Treatment and Outcomes (3 papers). Michael Evans‐Brown collaborates with scholars based in Portugal, United Kingdom and Denmark. Michael Evans‐Brown's co-authors include Roumen Sedefov, Jim McVeigh, Rachel Christie, Andreas Kimergård, Harry Sumnall, Ana Gallegos, István Ujváry, Anabela Almeida, Andrew Cunningham and Simon Elliott and has published in prestigious journals such as SHILAP Revista de lepidopterología, Addiction and BMJ Open.

In The Last Decade

Michael Evans‐Brown

28 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Evans‐Brown Portugal 13 353 173 164 162 117 28 700
Adam Negrusz United States 19 535 1.5× 144 0.8× 120 0.7× 114 0.7× 154 1.3× 45 1.0k
O. Quintela Spain 24 772 2.2× 143 0.8× 115 0.7× 236 1.5× 149 1.3× 62 1.4k
Fabio Vaiano Italy 20 555 1.6× 245 1.4× 65 0.4× 163 1.0× 154 1.3× 49 891
Jeri D. Ropero‐Miller United States 17 483 1.4× 170 1.0× 70 0.4× 119 0.7× 115 1.0× 51 914
Islam Amine Larabi France 14 245 0.7× 90 0.5× 82 0.5× 131 0.8× 55 0.5× 61 587
Douglas Lewis United States 19 306 0.9× 70 0.4× 61 0.4× 177 1.1× 88 0.8× 43 1.1k
Sven Härtwig Germany 13 384 1.1× 97 0.6× 69 0.4× 92 0.6× 79 0.7× 57 898
Enrico Gerace Italy 22 970 2.7× 388 2.2× 206 1.3× 223 1.4× 240 2.1× 54 1.3k
Mireia Ventura Spain 17 691 2.0× 364 2.1× 31 0.2× 206 1.3× 237 2.0× 51 945
Klaas J. Lusthof Netherlands 17 517 1.5× 151 0.9× 32 0.2× 138 0.9× 92 0.8× 30 967

Countries citing papers authored by Michael Evans‐Brown

Since Specialization
Citations

This map shows the geographic impact of Michael Evans‐Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Evans‐Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Evans‐Brown more than expected).

Fields of papers citing papers by Michael Evans‐Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Evans‐Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Evans‐Brown. The network helps show where Michael Evans‐Brown may publish in the future.

Co-authorship network of co-authors of Michael Evans‐Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Evans‐Brown. A scholar is included among the top collaborators of Michael Evans‐Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Evans‐Brown. Michael Evans‐Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brandt, Simon D., et al.. (2025). Update from the EU Early Warning System on new psychoactive substances. Annales de Toxicologie Analytique. 37(1). S22–S22. 1 indexed citations
2.
Evans‐Brown, Michael, Ana Gallegos, Rachel Christie, et al.. (2024). Recreational Use of Nitrous Oxide – a Growing Concern in Europe. SHILAP Revista de lepidopterología. 4. 100085–100085. 5 indexed citations
3.
4.
Jorge, Rodrigo, et al.. (2020). EMCDDA technical report on the new psychoactive substance methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA).. Liverpool John Moores University. 4 indexed citations
5.
Jorge, Rodrigo, et al.. (2020). EMCDDA technical report on the new psychoactive substance methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA).. Liverpool John Moores University. 8 indexed citations
6.
Evans‐Brown, Michael & Roumen Sedefov. (2018). Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures. Handbook of experimental pharmacology. 252. 3–49. 30 indexed citations
7.
Elliott, Simon, Roumen Sedefov, & Michael Evans‐Brown. (2017). Assessing the toxicological significance of new psychoactive substances in fatalities. Drug Testing and Analysis. 10(1). 120–126. 40 indexed citations
8.
Elliott, Sean J., et al.. (2017). Technical report on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide (tetrahydrofuranylfentanyl; THF-F). Annex 1 to the Risk Assessment Report on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2- carboxamide (tetrahydrofuranylfentanyl).. Liverpool John Moores University. 2 indexed citations
9.
Mounteney, Jane, Paul Griffiths, Andrew Cunningham, et al.. (2016). Continued signs of resilience in the European drug market: Highlights from the EMCDDA’s 2016 European drug report. Drugs Education Prevention and Policy. 23(6). 492–495. 5 indexed citations
10.
Evans‐Brown, Michael. (2015). Toxicovigilance of new psychoactive substances – Perspectives from the EU Early Warning System. Toxicology Letters. 238(2). S5–S5. 6 indexed citations
11.
Hope, Vivian, Jim McVeigh, Andrea Marongiu, et al.. (2014). Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiology and Infection. 143(1). 132–140. 44 indexed citations
12.
Abbate, Vincenzo, Andrew T. Kicman, Michael Evans‐Brown, et al.. (2014). Anabolic steroids detected in bodybuilding dietary supplements – a significant risk to public health. Drug Testing and Analysis. 7(7). 609–618. 63 indexed citations
13.
Breindahl, Torben, Michael Evans‐Brown, Peter Hindersson, et al.. (2014). Identification and characterization by LC‐UV‐MS/MS of melanotan II skin‐tanning products sold illegally on the Internet. Drug Testing and Analysis. 7(2). 164–172. 16 indexed citations
14.
Griffiths, Paul, Michael Evans‐Brown, & Roumen Sedefov. (2014). The (mis)use of psychoactive medicines: getting the balance right in complex systems. Addiction. 109(2). 182–183. 6 indexed citations
15.
Hope, Vivian, Jim McVeigh, Andrea Marongiu, et al.. (2013). Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 3(9). e003207–e003207. 90 indexed citations
16.
McVeigh, Jim, Michael Evans‐Brown, & Mark A Bellis. (2012). Drogas potenciadoras para la búsqueda de la perfección. Adicciones. 24(3). 185–185. 1 indexed citations
17.
Sumnall, Harry, Michael Evans‐Brown, & Jim McVeigh. (2011). Social, policy, and public health perspectives on new psychoactive substances. Drug Testing and Analysis. 3(7-8). 515–523. 63 indexed citations
18.
Evans‐Brown, Michael, Mark A Bellis, & Jim McVeigh. (2011). Should "legal highs" be regulated as medicinal products?. BMJ. 342(feb23 2). d1101–d1101. 6 indexed citations
19.
Evans‐Brown, Michael, Andreas Kimergård, & Jim McVeigh. (2009). Elephant in the room? The methodological implications for public health research of performance‐enhancing drugs derived from the illicit market. Drug Testing and Analysis. 1(7). 323–326. 26 indexed citations
20.
Evans‐Brown, Michael & Jim McVeigh. (2009). Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom. Journal of Substance Use. 14(5). 267–288. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adam Negrusz Breakdown of academic impact, for papers by O. Quintela Breakdown of academic impact, for papers by Fabio Vaiano Breakdown of academic impact, for papers by Jeri D. Ropero‐Miller Breakdown of academic impact, for papers by Islam Amine Larabi Breakdown of academic impact, for papers by Douglas Lewis Breakdown of academic impact, for papers by Sven Härtwig Breakdown of academic impact, for papers by Enrico Gerace Breakdown of academic impact, for papers by Mireia Ventura Breakdown of academic impact, for papers by Klaas J. Lusthof
Rankless by CCL
2026